Chemomab Stock Analysis

CMMB -  USA Stock  

USD 20.64  0.75  3.51%

The current slip in stock price could raise concerns from investors as the firm it trading at a share price of 20.64 on 308,400 in volume. The company executives have failed to build on market volatilities in May. However, diversifying your overall positions with Chemomab Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 16.29. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Chemomab Therapeutics partners.
Continue to Trending Equities.

Search Stock Analysis 

The Chemomab Therapeutics stock analysis report makes it easy to digest most publicly released information about Chemomab Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Chemomab stock analysis module also helps to analyze the Chemomab Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Chemomab Stock Analysis Notes

The company had not issued any dividends in recent years. Chemomab Therapeutics had a split on the 17th of March 2021. ChemomAb Ltd. develops therapeutic antibodies for the treatment of autoimmune and inflammatory diseases. Chemomab Therapeutics is traded on NASDAQ Exchange in the United States. For more info on Chemomab Therapeutics please contact the company at 972 5 2331 6862 or go to

Chemomab Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Chemomab Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Chemomab Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Chemomab Therapeutics generates negative expected return over the last 90 days
Chemomab Therapeutics has high historical volatility and very poor performance
Chemomab Therapeutics has high likelihood to experience some financial distress in the next 2 years
Latest headline from What You Need To Know About Chemomab Therapeutics Ltd.s Investor Composition - Yahoo Finance

Chemomab Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Chemomab Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Chemomab Therapeutics backward and forwards among themselves. Chemomab Therapeutics' institutional investor refers to the entity that pools money to purchase Chemomab Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Orbimed Advisors LlcCommon Shares2.6 M74 M
Maven Securities LtdCommon Shares126.6 K3.6 M
Cvi Holdings LlcCommon Shares93.8 K2.7 M
Boothbay Fund Management LlcCommon Shares61.8 K1.8 M
Meitav Dash Investments LtdCommon Shares8.3 K239 K
Renaissance Technologies LlcCommon SharesK202 K
Ubs Group AgCommon Shares83424 K
Note, although Chemomab Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Chemomab Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 94.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chemomab Therapeutics's market, we take the total number of its shares issued and multiply it by Chemomab Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

Chemomab Therapeutics management efficiency ratios could be used to measure how well chemomab therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 19th of June, Chemomab Therapeutics shows the mean deviation of 7.13, and Risk Adjusted Performance of (0.003355). Chemomab Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen technical drivers for Chemomab Therapeutics, which can be compared to its rivals. Please confirm Chemomab Therapeutics downside deviation, treynor ratio, expected short fall, as well as the relationship between the variance and potential upside to decide if Chemomab Therapeutics is priced correctly, providing market reflects its regular price of 20.64 per share. Given that Chemomab Therapeutics has jensen alpha of (0.52), we suggest you to validate Chemomab Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Chemomab Therapeutics Price Movement Analysis

The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. View also all equity analysis or get more info about mavp overlap studies indicator.

Chemomab Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Chemomab Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Chemomab Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Chemomab Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Chemomab Therapeutics Predictive Daily Indicators

Chemomab Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Chemomab Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Chemomab Therapeutics Forecast Models

Chemomab Therapeutics time-series forecasting models is one of many Chemomab Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Chemomab Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Chemomab Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Chemomab Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Chemomab shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Chemomab Therapeutics. By using and applying Chemomab Stock analysis, traders can create a robust methodology for identifying Chemomab entry and exit points for their positions.
ChemomAb Ltd. develops therapeutic antibodies for the treatment of autoimmune and inflammatory diseases. Chemomab Therapeutics is traded on NASDAQ Exchange in the United States.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Chemomab Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Efficient Frontier Now


Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
All  Next Launch Module
Continue to Trending Equities. Note that the Chemomab Therapeutics information on this page should be used as a complementary analysis to other Chemomab Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Chemomab Therapeutics Stock analysis

When running Chemomab Therapeutics price analysis, check to measure Chemomab Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemomab Therapeutics is operating at the current time. Most of Chemomab Therapeutics' value examination focuses on studying past and present price action to predict the probability of Chemomab Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemomab Therapeutics' price. Additionally, you may evaluate how the addition of Chemomab Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Transaction History
View history of all your transactions and understand their impact on performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Chemomab Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.